fda compounding semaglutide warning letters october 2025 Beyond the Headlines: to GLP-1 Compounders FDA Warns Novo Nordisk on

Can tailor dosage to individual needs Often more cost-effective than brand-name drugs Available through licensed, verified providers While oversight differs from large pharmaceutical companies, many compounding pharmacies follow strict state and federal standards

Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a Meta-analysis of the EXSCEL and FIGHT trials

It enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system effects

North America dominates the market with share of 73% CAGR in 2022, and is anticipated to grow with 17% CAGR over the forecast period 2023-2029

Clinical trials show the true potential of Retatrutide is 24% weight loss or more

Tirzepatide vs Retatrutide for Weight Loss When comparing pure weight loss potential, retatrutide currently appears to produce greater average reductions in body weight based on available research